Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 6/20 | 0.49 |
| ▸ | AVPR1B | P47901 | 6/20 | 0.49 |
| ▸ | OXTR | P30559 | 5/20 | 0.49 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.49 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 4/20 | 0.42 |
| ▸ | CBX7 | O95931 | 1/20 | 0.36 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.36 |
| ▸ | SNRNP200 | O75643 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5349226 | 0.92 | AVPR1A (0.54) | AVPR1AAVPR1BOXTRAVPR2GPR65 | |
| SCHEMBL5366688 | 0.87 | AVPR1A (0.62) | AVPR1AAVPR1BOXTRAVPR2GPR65 | |
| SCHEMBL1465619 | 0.87 | AVPR1A (0.62) | AVPR1AAVPR1BOXTRAVPR2GPR65 | |
| SCHEMBL2499523 | 0.86 | AVPR1A (0.55) | AVPR1AAVPR1BOXTRAVPR2GPR65 | |
| SCHEMBL2501951 | 0.86 | AVPR1A (0.54) | AVPR1AAVPR1BOXTRAVPR2GPR65 | |
| SCHEMBL5351154 | 0.85 | AVPR1A (0.49) | AVPR1AAVPR1BOXTRAVPR2GPR65 | |
| SCHEMBL1465123 | 0.85 | AVPR1B (0.62) | AVPR1AAVPR1BOXTRAVPR2GPR65 | |
| SCHEMBL2492934 | 0.84 | AVPR1A (0.53) | AVPR1AAVPR1BOXTRAVPR2GPR65 | |
| SCHEMBL2497748 | 0.84 | AVPR1A (0.51) | AVPR1AAVPR1BOXTRAVPR2GPR65 | |
| SCHEMBL2497100 | 0.84 | AVPR1B (0.51) | AVPR1AAVPR1BOXTRAVPR2GPR65 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | AVPR1B, AVPR1A, AVPR2 | AVPR1A 2/4885AVPR1B 1/4885OXTR 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.